Drug Profile

AEM 28

Alternative Names: AEM-28; Apolipoprotein E mimetic

Latest Information Update: 14 May 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Alabama at Birmingham
Developer LipimetiX Development
Class Antihyperlipidaemics; Apolipoprotein therapeutics; Peptides
Mechanism of Action Apolipoprotein B modulators; Apolipoprotein E agonists; Cholesterol modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hyperlipoproteinaemia type IIa
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

07 May 2018 AEM 28 licensed to Anji Pharma in China, Taiwan and Hong Kong
26 Aug 2016 AEM 28 is available for licensing as of 29 Jul 2016. http://www.lipimetix.com/businessmodel.html
25 Aug 2016 Phase-II development is ongoing in Australia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com